FDA
-
-
-
-
-
-
-
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Solid Biosciences licenses capsid technology to Andelyn Biosciences
-
-
-
-
-
-
-
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
-
-
-
-
-
-
-
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
-
-
-
-
-
-
-
Solid Biosciences (SLDB) PT Lowered to $17 at Piper Sandler
-
-
-
-
-
-
-
Drugmakers sink after key FDA official ousted as Trump plans health overhaul
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

